IL3RA Specific Neutra™ Antibody Products
Product listIL3RA, being the principal ligand-binding subunit of the heterodimeric receptor IL-3R, is ubiquitously expressed in IL3-responsive cells including hematopoietic stem cells, megakaryocytes, monocytes, B lymphocytes, and others. It plays a key role in mediating basic cellular behaviors such as cell proliferation, survival, and differentiation, while also participating in immune and inflammatory responses.
Its Gene ID: 3563, UniProtKB ID: P26951, and OMIM ID: 430000.
The Biology of IL3RA
IL3RA represents an attractive biomarker for the diagnosis and intervention of neoplastic diseases, particularly those malignancies of bone marrow and lymphatic origins. Additionally, it has been proven that the activation of IL3RA can regulate the activation and functionality of basophils or mast cells in mature immune cells.
IL3RA performs its biological functions predominantly via binding with IL-3; the assembly of IL-3/IL-3R complexes triggers the activation of the downstream networks JAK/ATAT, MAPK, and PI3K/AKT, which thereby drives hematopoietic cell development and promotes terminal differentiation of bone marrow cells.
Fig.1 IL3RA signaling pathway.1
The Pathology of IL3RA
IL3RA is overexpressed on the surface of various malignant hematological tumors including acute lymphoblastic leukemia, hairy cell leukemia, chronic granulocytic monocytic leukemia, myelodysplastic syndromes, Hodgkin's lymphoma, and more. While its pathological functionality remains not entirely elucidated, extensive screening views IL3RA as potentially correlated with poorer prognosis of tumor intervention, therefore making it an attractive diagnostic and prognostic biomarker for malignant hematological tumors.
Fig.2 IL3RA (CD123) therapeutics.2
The Therapeutic Significance of IL3RA
The development of targeted tumor intervention strategies focusing on IL3RA renders it as an indispensable biomarker in present practices. Current situations and strategies of IL3RA targeted interventions include:
- The recombinant diphtheria toxin/IL-3 fusion protein has been authorized by the FDA and granted orphan drug designation.
- Humanized anti-IL3RA mAb as monotherapy or in combination is under research yet still of unfavorable risk profile.
- Antibody-drug conjugates show certain feasibility in anti-tumor therapy, now in pre-clinical evaluation and development.
- The bispecific antibody that simultaneously recognizes IL3RA and CD3 has entered the early stages of clinical trials.
- T cells engineered with CAR-expressing IL3RA-specific antigen receptors have reached the early phases of clinical investigation.
Years of relentless efforts have endowed Creative Biolabs with the confidence to offer our global clients one-stop, comprehensive services related to IL3RA. You will not only enjoy the endless benefits from our cutting-edge neutralizing antibody and recombinant antibody platforms but also explore our IL3RA-related product library to initiate your study swiftly.
REFERENCES
- Patnait, Mughal, et al. "Targeting IL3RA in hematologic malignancies: identifying suitable patients for targeted therapy." Leukemia and Lymphoma 10 (2021): 1927021.
- Achi, Dupont, et al. "IL3RA as a Biomarker in Hematolymphoid Malignancies: Principles of Detection and Targeted Therapies." Cancers 12 (2020): 3087.
